EX-99.1 2 ex99_1.htm EXHIBIT 99.1 ex99_1.htm

Exhibit 99.1
 
2011 UBS Global Life Sciences Conference
September 20, 2011
 
 

 
Forward Looking Statements
This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty
revenues, expenses, net income, and cash provided by operating activities.
Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those,
express or implied, in these forward-looking statements. Factors that may cause differences between current expectations
and actual results include, but are not limited to, the following:
 The expected rate of growth in royalty-bearing product sales by PDL’s existing licensees;
 The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or
 sold in the U.S.;
 The ability of PDL’s licensees to receive regulatory approvals to market and launch new royalty-bearing products and
 whether such products, if launched, will be commercially successful;
 Changes in any of the other assumptions on which PDL’s projected royalty revenues are based;
 Changes in foreign currency rates;
 Positive or negative results in PDL’s attempt to acquire royalty-related assets;
 The outcome of pending litigation or disputes, including PDL’s current dispute with Genentech related to ex-U.S. sales of
 Genentech licensed products; and
 The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.
Other factors that may cause PDL’s actual results to differ materially from those expressed or implied in the forward-
looking statements in this presentation are discussed in PDL’s filings with the SEC, including the "Risk Factors" sections of
its annual and quarterly reports filed with the SEC. Copies of PDL’s filings with the SEC may be obtained at the "Investors"
section of PDL’s website at 
www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in PDL’s expectations with
regard thereto or any change in events, conditions or circumstances on which any such statements are based for any
reason, except as required by law, even as new information becomes available or other events occur in the future. All
forward-looking statements in this presentation are qualified in their entirety by this cautionary statement.
2
 
 
 

 
Company
PDL BioPharma, Inc.
Ticker
PDLI (NASDAQ)
Location
Incline Village, Nevada
Employees
Less than 10
2010 Revenues
$345 million
2011- Q3YTD Revenue
Guidance
$288 million
2011 Regular Dividends
$0.15 /share paid on March 15, June 15,
September 15 & December 15
Q2-2011 Cash Position1
$236 million
Shares O/S2
~ 140 million
Average Daily Volume
~ 3 million shares
Key Information
3
1. As of June 30, 2011; 2. Not fully diluted
 
 

 
Overview of PDL BioPharma
4
 
 

 
Company Overview
 PDL pioneered the humanization of monoclonal antibodies
 which enabled the discovery of a new generation of targeted
 treatments for cancer and immunologic diseases
 PDL’s primary assets are its antibody humanization patents
 and royalty assets which consist of its Queen et al. patents
 and license agreements
 Licensees consist of large biotechnology and
 pharmaceutical companies including Roche/Genentech/
 Novartis, Elan/BiogenIdec, Pfizer/Wyeth/J&J and Chugai
5
 
 

 
Antibody Humanization Technology
 Antibodies are naturally produced by humans to fight
 foreign substances, such as bacteria and viruses
 In the 1980’s, scientists began creating antibodies in non
 -human immune systems, such as those of mice, that
 could target specific sites on cells to fight various human
 diseases
 However, mouse derived antibodies are recognized by
 the human body as foreign substances and may be
 rejected by the human immune system
6
 PDL’s technology allows for the “humanization” of mouse derived antibodies by moving the
 important binding regions from the mouse antibody onto a human framework
 PDL’s humanization technology is important because the humanized antibodies retain the
 binding and activity levels from the original mouse antibody
 PDL’s technology has been incorporated into antibodies to treat cancer, eye diseases,
 arthritis, multiple sclerosis and other health conditions with aggregate annual sales of over
 $17 billion
 
 

 
Mission Statement
 Queen et al. Patents
  Manage patent portfolio
  Manage license agreements
 
 Purchase new royalty generating assets
  Assets that improve shareholder return
  Commercial stage assets
  Prefer biologics with strong patent protection
 
 Optimize return for shareholders
7
 
 

 
Corporate Governance
Management
 John McLaughlin
 
President & CEO
 Christine Larson
 
VP & CFO
 Christopher Stone
 
VP, General Counsel &
 Secretary
 Caroline Krumel
 
VP of Finance
 Danny Hart
 
Associate General Counsel
Board of Directors
 Fred Frank
 
Lead Director
 Jody Lindell
 John McLaughlin
 Paul Sandman
 Harold Selick
8
 
 

 
Licensed Products and Royalty Revenue
9
 
 

 
Licensed Products and Royalty Revenue
10
1. As reported to PDL by its licensee 2. As reported by Roche; assume 1.155 CHF/USD
 
 

 
How Long Will PDL Receive Royalties from
Queen et al. Patents?
 PDL’s revenues consist of royalties generated on sales of licensed products
  Sold before the expiration of the Queen et al. patents in mid-2013 through end of 2014
 or
  Made prior to the expiration of the Queen et al. patents and sold anytime thereafter
11
Example of Antibody Formulation, Fill and Finish Schedule
½ month
1 month
½ month
2-3 months
Thaw, Formulation &
Vial Filling
Quality
Release
Packaging
& Quality
Inventory
Example of Antibody Bulk Manufacturing Schedule
Cell
Culture
Quality Release
Testing
Bulk Frozen Storage
1 mo
3 mos
5 mos
10 mos
15 mos
20 mos
27 mos
3 mos
2-18 months
1mo
1mo
Purification to Concentrated Bulk/Frozen
 
 

 
Genentech Product Made or Sold in U.S.
 
Net Sales up to $1.5 Billion
3.0%
Net Sales Between $1.5 Billion and $2.5 Billion
2.5%
Net Sales Between $2.5 Billion and $4.0 Billion
2.0%
Net Sales Over $4.0 Billion
1.0%
Genentech Product Made and Sold Ex-U.S.
 
All Sales
3.0%
Queen et al Patents - Royalty Rates
12
 Tysabri and Actemra
  Flat, low single-digit royalty
 Genentech Products (Avastin, Herceptin, Lucentis1 and Xolair)
  Tiered royalties on product made or sold in US
  Flat, 3% royalty on product made and sold outside US
  Blended global royalty rate on Genentech Products in 2010 was 1.9%
  Blended royalty rate on Genentech Products in 2010 made or sold in US was
 1.5%
1. As part of a settlement with Novartis, which commercializes Lucentis outside US, PDL agreed to pay to Novartis
certain amounts based on net sales of Lucentis made by Novartis during calendar year 2011 and beyond. The
amounts to be paid are less than we receive in royalties on such sales and we do not currently expect such amount to
materially impact our total annual revenues.
 
 

 
Shift of Manufacturing Sites = Higher Royalties
 Roche is moving some manufacturing ex-US which may result in higher royalties to PDL
 due to the flat 3% royalty for Genentech Products made
and sold ex-US
  Current production at Penzburg (Herceptin) and Basel (Avastin) plants
  Two new plants in Singapore (CHO = antibody and e. coli = antibody fragment)
 - E. coli (Lucentis) and CHO (Avastin) plants are approved for commercial supply to the US
 - E. coli and CHO plants are expected to be approved for commercial supply to the EU in 2011
 - Currently, all Lucentis is made in the US
13
1. As reported to PDL by its licensee
 
 

 
Royalty Revenue & Licensed Products
14
Royalties by Product
($ in millions)
 
 

 
Royalty Products - Approved
15
 
 

 
Royalty Products - Avastin
16
Avastin
Herceptin
Lucentis
Xolair
Tysabri
RoActemra
ü On June 29, 2011, an advisory committee to FDA voted
 unanimously that the approval of Avastin for the treatment of
 HER2- breast cancer should be revoked
ü Final decision rests with the FDA Commissioner, FDA
 determined on December 16, 2010 to withdraw Avastin’s
 approval as first line treatment for HER2- breast cancer in
 combination with paclitaxel.
ü Genentech has submitted a new proposal to maintain the
 approval with more restrictive labeling, REMS and a
 commitment to conduct a new 480 patient confirmatory trial.
ü EMEA narrowed, but did not withdraw Avastin’s approval for
 first line treatment of HER2- breast cancer in combination with
 paclitaxel or with Xeloda.
ü Roche lowered its estimate of peak annual sales from of
 Avastin from CHF8 - CHF9 billion to CHF7 billion.
ü Based on our internal model, we project Avastin for treatment
 of metastatic HER2- breast cancer represents slightly more
 than 2% of total PDL royalty revenue.
 
 

 
Royalty Products - Avastin
17
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On June 4, 2011, Genentech announced results from Phase 3
 study evaluating Avastin in combination with chemotherapy
 (gemcitabine and carboplatin) followed by the continued use of
 Avastin alone in women with previously treated (recurrent)
 platinum-sensitive ovarian cancer which showed that women
 who received Avastin experienced a 52% reduction in the risk
 of their disease progressing (HR=0.48, p<0.0001) compared to
 women who received chemotherapy alone.
ü Two previous Phase 3 studies in women with newly diagnosed
 ovarian cancer demonstrated that front-line Avastin in
 combination with standard chemotherapy (carboplatin and
 paclitaxel), followed by the continued use of Avastin alone,
 significantly increased progression free survival compared to
 treatment with chemotherapy alone.
ü Roche has submitted an application for approval for first line
 treatment in EU and expects a decision later in 2011.
ü Genentech expects to file an application for approval in US in
 late 2011 so that it can meet FDA’s request for overall survival
 data.
 
 

 
Royalty Products - Lucentis
18
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On January 7, 2011, Novartis announced that Lucentis has
 been approved in the EU for the treatment of visual impairment
 due to diabetic macular edema (DME).
 § DME is a leading cause of blindness in the working-age
 population in most developed countries.
ü On February 11, 2011, Genentech announced that one of two
 Phase 3 studies evaluating patients with DME showed that a
 significantly higher percentage of patients receiving monthly
 dosing of Lucentis achieved an improvement in vision of at
 least 15 letters on the eye chart at 24 months compared to
 those in a control group, who received a placebo injection.
ü On June 6, 2011, Novartis announced that Lucentis has been
 approved in the EU for the treatment of visual impairment due
 to macular edema secondary to retinal vein occlusion.
 
 

 
Royalty Products - Lucentis
19
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On November 22, 2010, Regeneron and Bayer reported top line
 data from two Phase 3 trials investigating VEGF Trap in age-related
 macular degeneration (AMD) patients which suggest that it may be
 injected into the eye every other month with safety and efficacy
 comparable to that of monthly dosing of Lucentis.
ü On December 20, 2010, Regeneron reported positive Phase 3 data
 in the treatment of retinal vein occlusion (RVO) for which Lucentis is
 approved.
 § Unlike the AMD trial, monthly administration was used in the
 RVO trial, which does not afford a dosing advantage with
 respect to Lucentis.
ü On February 22, 2011, Regeneron and Bayer filed an application for
 approval of VEGF Trap for AMD with an initial PDUFA date of
 August 20, 2011 which was subsequently extended to November
 18, 2011. An FDA Advisory Committee recommended approval of
 VEGF Trap on June 17, 2011.
ü On June 7, 2011, Regeneron and Bayer filed an application for AMD
 in EU.
ü Regeneron filed suit in February 2011 seeking a summary judgment
 that it does not infringe Genentech’s patents.
ü Genentech filed a countersuit in April 2011 asserting that
 Regeneron is willfully infringing Genentech’s patents, seeking treble
 damages and asking for injunctive relief.
 
 

 
Royalty Products - Lucentis
20
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On April 4, 2011, Genentech and Johns Hopkins University
 reported results of a review of files of 77,886 patients with AMD
 who received either Avastin off-label or Lucentis.
ü Patients receiving Avastin off-label had an 11% increased risk
 of overall mortality, 57% increased risk of hemorrhagic
 cerebrovascular accident, 80% more likely to have ocular
 inflammation and 11% more likely to have cataract surgery
 following treatment than Lucentis treated patients.
ü Authors of the study note that it is limited due to incomplete
 information on confounding factors such as smoking, lipid and
 blood pressure levels, etc.
 
 

 
Royalty Products - Lucentis
21
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On April 28, 2011, New England Journal of Medicine reported
 the results from the NEI’s CATT study comparing Lucentis and
 Avastin on fixed and variable schedules in the treatment of
 AMD.
ü Efficacy results from the first year of the two year study showed
 that, with respect to the primary endpoint of mean change in
 visual acuity (number of lines of letters on an eye chart) at 12
 months, less expensive Avastin was not inferior to Lucentis.
 § It is estimated that off label use of Avastin in the U.S. was
 60% prior to the results of the CATT trial.
ü At 12 months, serious adverse events (primarily
 hospitalizations) occurred at a 24% rate for patients receiving
 Avastin and a 19% rate for patients receiving Lucentis.
 However, preliminary 24 month safety data showed no
 difference between Lucentis and Avastin treated patients in
 terms of death, stroke and all arteriothrombotic events.
ü On August 30, 2011, FDA issued a health warning alert after at
 least 16 AMD patients suffered eye infections after being
 treated with repackaged Avastin.
 
 

 
Royalty Products - Lucentis
22
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On June 28, 2011, Genentech reported positive results from
 two pivotal Phase 3 clinical studies in patients with diabetic
 macular edema.
ü Both studies showed that patients treated with Lucentis
 experienced significant, rapid and sustained improvement in
 vision compared to those who received sham injections.
ü  Additional analyses showed that patients who received
 Lucentis were significantly more likely to achieve 20/40 vision
 and experience less progression of underlying diabetic
 retinopathy disease.
 
 

 
Royalty Products - Tysabri
23
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü FDA and EMEA have included JC virus (JCV) status as a risk
 factor for PML in the product label for Tysabri.
 § The EMEA also recommended a five-year renewal of the
 Tysabri’s Marketing Authorization in the EU.
 § EMEA Physician Info Document states that risk of PML in:
 o JCV- patients is <0.2 per 1000
 o JCV+ patients with no prior immunosuppressants is 0.4
 per 1000 in first two years
 o JCV+ patients with no prior immunosuppressants is 2.6
 per 1000 in years 2-4
 o JCV+ patients AND prior immunosuppressants AND 2 or
 more years is 9 per 1000
 o JCV+ = roughly 55% of MS population
ü Net patient adds increased to 2400 in 2Q11, up from 1900 in
 1Q11.
 
 

 
Royalty Products - Actemra
24
Avastin
Herceptin
Lucentis
Xolair
Tysabri
Actemra
ü On January 5, 2011, Roche announced that FDA expanded the
 Actemra label to include inhibition and slowing of structural joint
 damage, improvement of physical function, and achievement of
 major clinical response in adult patients with moderately to
 severely active rheumatoid arthritis.
ü On April 18, 2011, FDA approved Actemra to treat patients age
 2 and older with active systemic juvenile idiopathic arthritis
 (SJIA).
 § It is the first and only approved treatment for SJIA, a rare
 and severe form of arthritis affecting children.
ü On July 19, 2011, Chugai/Roche announced that a
 subcutaneous formulation of Actemra has shown efficacy in
 rheumatoid arthritis comparable to the approved intravenous
 formulation. Based on these non-inferiority data, the company
 plans to file for approval in Japan in 2012.
 
 

 
Potential Royalty Products
- Development Stage
25
 
 

 
Potential Royalty Products - T-DM1
26
T-DM1
Breast HER2+ Cancer
ü On October 13, 2010, Roche/Genentech announced
 preliminary, six month results from a Phase 3 trial in second
 line HER2+ breast cancer patients which showed that 48% of
 women treated with T-DM1 had their tumors shrink compared
 with 41% of those taking the combination of Herceptin and
 Taxotere.
 § Among the women taking the standard therapy, 75% had
 side effects of grade 3 or higher on a 5-point scale,
 compared with 37% of those getting T-DM1.
ü Roche/Genentech expect to file for second line approval in
 2012.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Ocrelizumab
27
T-DM1
Breast HER2+ Cancer
ü Phase 2b.
ü Unlicensed product.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Pertuzumab
28
T-DM1
Breast HER2+ Cancer
ü On December 10, 2010, Roche/Genentech reported the results
 from a Phase 2 trial investigating the neoadjuvant (prior to
 surgery) use of pertuzumab and Herceptin plus chemotherapy
 for the treatment of early-stage, HER2+ breast cancer.
ü Treatment significantly improved the rate of complete tumor
 disappearance in the breast by more than half compared to
 Herceptin plus docetaxel, p=0.014.
ü On July 15, 2011, Roche/Genentech reported the results from
 a Phase 3 trial in pertuzumab plus Herceptin and docetaxel
 met the primary endpoint of progression-free survival (PFS) vs.
 Herceptin plus docetaxel alone
ü Roche/Genentech expect to file for approval at the end of
 2011.
ü Unlicensed product.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Afutuzumab
29
T-DM1
Breast HER2+ Cancer
ü Phase 3.
ü Roche/Genentech expect to file for approval in 2013.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Bapineuzumab
30
T-DM1
Breast HER2+ Cancer
ü Phase 3.
ü On July 19, 2011, researchers from Pfizer and Johnson &
 Johnson reported long-term safety of 194 patients in a mid-
 stage trial of the drug that stayed on treatment after the initial
 phase ended.
 § The brain swelling condition called vasogenic edema,
 which caused safety concerns early on in the trial, may
 decrease over time.
ü Data expected in second half of 2012.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Solanezumab
31
T-DM1
Breast HER2+ Cancer
ü Phase 3.
ü Data expected in second half of 2012.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Datoluzumab
32
T-DM1
Breast HER2+ Cancer
ü Phase 2.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Daclizumab
33
T-DM1
Breast HER2+ Cancer
ü Positive efficacy data reported from first of two Phase 3 trials.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Potential Royalty Products - Farletuzumab
34
T-DM1
Breast HER2+ Cancer
ü Phase 3.
Ocrelizumab
Multiple Sclerosis
Pertuzumab
Breast HER2+ Cancer
Afutuzumab
Chronic Lymphocytic
Leukemia
Solanezumab
Alzheimer’s Disease
Daclizumab
Multiple Sclerosis
Datoluzumab
Colorectal Cancer
Bapineuzumab
Alzheimer’s Disease
Farletuzumab
Ovarian Cancer
 
 

 
Genentech / Roche - Product Pipeline
2011
2012
2013
2014
Avastin
Ovarian Cancer 1st Line US
Lucentis
Diabetic Macular Edema (US)
Pertuzumab1
mBC HER2+ 1st Line
Avastin + Herceptin
mBC HER+ 2nd Line
Avastin
Relapsed Ovarian Cancer
T-DM1
HER 2+ Advanced mBC
Actemra
RA DMARD H2H (EU)
Actemra
Ankylosing Spondylitis
Herceptin
Subcutaneous Formulation
Avastin & Herceptin
HER2+ mBC 1st Line
Avastin
mCRC TML
Actemra
SC Formulation (EU)
Afutuzumab (GA101)
Chronic Lymphocytic Leukemia
Actemra
Early Rheumatoid Arthritis
Avastin
BC Adjuvant HER2+
Avastin
BC Adj Triple Negative
Herceptin
BC HER 2+ Adj 2 Year
Xolair
Chronic Idiopathic Urticaria
Avastin
Glioblastoma 1st Line
Actemra
SC Formulation (US)
Lucentis
AMD High Dose (US)
T-DM1
HER 2+ mBC 1st Line
Ocrelizumab1
PPMS & RRMS
1.Not a licensed product
Source: Roche investor update, July 21, 2011
US & EU Filings Calendar
 
 

 
Financials
36
 
 

 
Financial Overview
37
1. Includes $92.5 million one time legal settlement to MedImmune. Net interest expense includes
 $17.6 million loss on convertible note retirement.
2. Includes $10.0 million one time legal settlement from UCB.
 
 

 
Debt
38
 
 

 
Current and Long-Term Liabilities
 $155 million 3.75% senior convertible notes due May 2015
  Notes issued May 16, 2011; conversion rate is 132.6682 / $1,000 face amount ($7.54/share)
  Bond hedge effectively increases conversion price to $8.87 / share
  Notes “net share settle” and are excluded from diluted EPS
 $180 million 2.875% convertible senior notes due February 2015
  Conversion rate is 151.713 shares / $1,000 face amount ($6.59/share) 
 
39
  Approximately 40% of Genentech royalties
 dedicated to quarterly principal and interest
  After retirement, securitized Genentech
 royalties will be retained by PDL
 The purpose of restructuring PDL’s
 debt is to free up cash for the
 acquisition of new royalty assets
 
 

 
Legal Matters
40
 
 

 
Recent Resolution of Legal Disputes
 PDL has resolved all challenges to the Queen et al. Patents in the
 U.S. Patent and Trademark Office (USPTO) and the European
 Patent Office (EPO) as well as its dispute with MedImmune
  UCB Pharma
 - PDL received $10 million from UCB and PDL agreed not to sue UCB for any royalties related
 to Cimzia
 - UCB terminated patent interference proceedings before the USPTO and withdrew its
 opposition appeal in the EPO
  MedImmune
 - PDL paid MedImmune $65 million on February 15, 2011, and will pay them an additional
 $27.5 million by February 2012
 - MedImmune ceased support of any party in the EPO opposition appeal
  Novartis
 - PDL dismissed its claims against Novartis in its Nevada lawsuit
 - Novartis withdrew its opposition appeal to PDL’s European patent in EPO
 - Beginning in 2Q11, PDL will pay Novartis an amount based on Novartis’ net ex-U.S. sales of
 Lucentis during calendar year 2011 and beyond
  BioTransplant
 - PDL acquired BioTransplant, a bankrupt company and instructed BioTransplant to withdraw
 its opposition appeal in the EPO
41
 
 

 
Pending Dispute with Genentech and Roche
 In August 2010, Genentech sent a fax on behalf of Roche and Novartis
 asserting its products do not infringe PDL’s supplementary protection
 certificates (SPCs)
  Products include Avastin, Herceptin, Lucentis and Xolair
  SPCs are patent extensions in Europe that are issued on a country-by-country and product
 -by-product basis
 
 PDL Response
  Genentech’s assertions are without merit
  PDL disagrees with Genentech’s assertions of non-infringement
  Genentech had waived its rights to challenge our patents, including SPCs in its 2003
 Settlement Agreement with PDL
 
 2003 Settlement Agreement
  Resolved intellectual property disputes between the two companies at that time
  Limits Genentech’s ability to challenge infringement of PDL’s patent rights, including
 SPCs, and waives Genentech’s right to challenge or assist other in challenging the validity
 of our patent rights
42
 
 

 
Nevada Lawsuit Against Genentech/Roche
 PDL filed a lawsuit against Genentech and Roche in Nevada state court
  Lawsuit states that fax constitutes a breach of 2003 Settlement Agreement because Genentech assisted
 Roche in challenging PDL’s patents and SPCs
  Complaint seeks compensatory damages, including liquidated damages and other monetary remedies
 set forth in the 2003 Settlement Agreement, punitive damages and attorney’s fees
 
 In November 2010, Genentech and Roche filed two motions to dismiss
  They contend that 2003 Settlement Agreement applies only to PDL’s U.S. patents
  They asserted that the Nevada court lacks personal jurisdiction over Roche
 
 On July 11, 2011, court denied Genentech and Roche's motion to dismiss four of
 PDL's five claims for relief and denied Roche's separate motion to dismiss for lack of
 personal jurisdiction.
  The court dismissed one of PDL's claims that Genentech committed a bad-faith breach of the covenant of
 good faith and fair dealing
 
 The court ruling allows PDL to continue to pursue its claims that:
  Genentech is obligated to pay royalties to PDL on international sales of the Genentech Products
  Genentech, by challenging, at the behest of Roche and Novartis, whether PDL's SPCs cover the
 Genentech Products breached its contractual obligations to PDL under the 2003 settlement agreement
  Genentech breached the implied covenant of good faith and fair dealing with respect to the 2003
 settlement agreement
  Roche intentionally and knowingly interfered with PDL's contractual relationship with Genentech in
 conscious disregard of PDL's rights
43
 
 

 
Optimizing Stockholder Return
44
 
 

 
Business Strategy
 Purchase new royalty assets and
 ladder like a bond portfolio
  Continue to reinvest in new royalty
 assets and pay dividends
 - Commercial stage products
 - Sweet spot $75MM to $150MM
  Debt repaid by end of 2015
  Company continues as long as it can
 generate satisfactory return
 If unable to acquire royalty assets on
 attractive terms, build cash reserves
 to:
  Repay debt
  Use all excess cash to pay dividends
 to enhance shareholder return
  Wind-up company in 2016 timeframe
45
 Queen et al. patents expire end of 2014;
 we anticipate royalties will likely continue
 to ~2016
 PDL has two possible future pathways
 
 

 
Optimizing Stockholder Return
 Continuously evaluating alternatives
  Dividends
  Capital restructure
  Share repurchase
  Company sale
  Purchase of commercial stage, royalty
 generating assets
46
 
 

 
Investment Highlights
 Strong historic revenue growth from approved products
 Potential for additional indications from existing products,
 new product approvals and purchase of new royalty assets
 Potential to grow and diversify revenues with the addition of
 new royalty assets
 Significantly reduced expenses with no R&D burn
 Liquidity - volume averages 3 million shares/day
 Return to stockholders
  In 2011, $0.60/share to be paid in quarterly regular dividends of
 $0.15/share on March 15, June 15, September 15 and
 December 15
47